• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Inozyme Pharma Inc. (Amendment)

    2/14/24 8:34:39 PM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INZY alert in real time by email
    SC 13G/A 1 tm246235d27_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G/A

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)*

     

    Inozyme Pharma, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

     

    45790W108

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)

     

      x Rule 13d-1(c)

     

      ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
    CUSIP No. 45790W108Page 2 of 17

     

               
    1.  

    Name of reporting persons

     

    Venrock Healthcare Capital Partners II, L.P.

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    0

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    0.0%

    12.  

    Type of Reporting Person (See Instructions)

     

    PN

                     
                     

    1    Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

     
    CUSIP No. 45790W108Page 3 of 17

     

               
    1.  

    Name of reporting persons

     

    VHCP Co-Investment Holdings II, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    0

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    0.0%

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

                     
                     

    1    Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

     
    CUSIP No. 45790W108Page 4 of 17

     

               
    1.  

    Name of reporting persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    0

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    0

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    0.0%

    12.  

    Type of Reporting Person (See Instructions)

     

    PN

                     

    1    Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

     
    CUSIP No. 45790W108Page 5 of 17

     

               
    1.  

    Name of reporting persons

     

    VHCP Co-Investment Holdings III, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    0

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    0

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    0.0%

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

                     

    1    Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

     
    CUSIP No. 45790W108Page 6 of 17

     

               
    1.  

    Name of reporting persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    0

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    0

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    0.0%

    12.  

    Type of Reporting Person (See Instructions)

     

    PN

                     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

     
    CUSIP No. 45790W108Page 7 of 17

     

               
    1.  

    Name of reporting persons

     

    VHCP Management II, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    0

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    0

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    0.0%

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

                     

    1    Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

     
    CUSIP No. 45790W108Page 8 of 17

     

               
    1.  

    Name of reporting persons

     

    VHCP Management III, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    0

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    0

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    0.0%

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

                     

    1    Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

     
    CUSIP No. 45790W108Page 9 of 17

     

               
    1.  

    Name of reporting persons

     

    VHCP Management EG, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    0

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    0

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    0.0%

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

                     

    1    Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

     
    CUSIP No. 45790W108Page 10 of 17

     

             
    1.  

    Name of Reporting Persons

     

    Shah, Nimish

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    0

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    0.0%

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

    1    Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

     
    CUSIP No. 45790W108Page 11 of 17

     

             
    1.  

    Name of Reporting Persons

     

    Koh, Bong

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    0

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    0.0%

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

    1    Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

     
    CUSIP No. 45790W108Page 12 of 17

     

    Introductory Note: This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners II, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP II LP”), VHCP Co-Investment Holdings II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment II”), Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management II”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP II LP, VHCP Co-Investment II, VHCP III LP, VHCP Co-Investment III, VHCP EG, VHCP Management II and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of Common Stock of Inozyme Pharma, Inc.

     

    Item 1.

     

      (a) Name of Issuer

     

    Inozyme Pharma, Inc.

     

      (b) Address of Issuer’s Principal Executive Offices

     

    321 Summer Street, Suite 400

    Boston, Massachusetts 02210

     

    Item 2.

     

      (a) Name of Person Filing

     

    Venrock Healthcare Capital Partners II, L.P.

    VHCP Co-Investment Holdings II, LLC

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management II, LLC

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     

      (b) Address of Principal Business Office or, if none, Residence

     

      New York Office: Palo Alto Office:
         
      7 Bryant Park 3340 Hillview Avenue
      23rd Floor Palo Alto, CA 94304
      New York, NY 10018  

     

      (c) Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     

      (d) Title of Class of Securities

     

    Common Stock, par value $0.0001 per share

     

      (e) CUSIP Number

     

    45790W108

     

     
    CUSIP No. 45790W108Page 13 of 17

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable

     

    Item 4. Ownership

     

      (a) Amount Beneficially Owned as of December 31, 2023:

     

    Venrock Healthcare Capital Partners II, L.P.     0  
    VHCP Co-Investment Holdings II, LLC     0  
    Venrock Healthcare Capital Partners III, L.P.     0  
    VHCP Co-Investment Holdings III, LLC     0  
    Venrock Healthcare Capital Partners EG, L.P.     0  
    VHCP Management II, LLC     0  
    VHCP Management III, LLC     0  
    VHCP Management EG, LLC     0  
    Nimish Shah     0  
    Bong Koh     0  

     

      (b) Percent of Class as of December 31, 2023:

     

    Venrock Healthcare Capital Partners II, L.P.     0.0 %
    VHCP Co-Investment Holdings II, LLC     0.0 %
    Venrock Healthcare Capital Partners III, L.P.     0.0 %
    VHCP Co-Investment Holdings III, LLC     0.0 %
    Venrock Healthcare Capital Partners EG, L.P.     0.0 %
    VHCP Management II, LLC     0.0 %
    VHCP Management III, LLC     0.0 %
    VHCP Management EG, LLC     0.0 %
    Nimish Shah     0.0 %
    Bong Koh     0.0 %

      

      (c) Number of shares as to which the person has, as of December 31, 2023:

     

      (i) Sole power to vote or to direct the vote

      

    Venrock Healthcare Capital Partners II, L.P.     0  
    VHCP Co-Investment Holdings II, LLC     0  
    Venrock Healthcare Capital Partners III, L.P.     0  
    VHCP Co-Investment Holdings III, LLC     0  
    Venrock Healthcare Capital Partners EG, L.P.     0  
    VHCP Management II, LLC     0  
    VHCP Management III, LLC     0  
    VHCP Management EG, LLC     0  
    Nimish Shah     0  
    Bong Koh     0  

     

     

     
    CUSIP No. 45790W108Page 14 of 17

     

      (ii) Shared power to vote or to direct the vote

     

    Venrock Healthcare Capital Partners II, L.P.     0  
    VHCP Co-Investment Holdings II, LLC     0  
    Venrock Healthcare Capital Partners III, L.P.     0  
    VHCP Co-Investment Holdings III, LLC     0  
    Venrock Healthcare Capital Partners EG, L.P.     0  
    VHCP Management II, LLC     0  
    VHCP Management III, LLC     0  
    VHCP Management EG, LLC     0  
    Nimish Shah     0  
    Bong Koh     0  

     

      (iii) Sole power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners II, L.P.     0  
    VHCP Co-Investment Holdings II, LLC     0  
    Venrock Healthcare Capital Partners III, L.P.     0  
    VHCP Co-Investment Holdings III, LLC     0  
    Venrock Healthcare Capital Partners EG, L.P.     0  
    VHCP Management II, LLC     0  
    VHCP Management III, LLC     0  
    VHCP Management EG, LLC     0  
    Nimish Shah     0  
    Bong Koh     0  

     

      (iv) Shared power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners II, L.P.     0  
    VHCP Co-Investment Holdings II, LLC     0  
    Venrock Healthcare Capital Partners III, L.P.     0  
    VHCP Co-Investment Holdings III, LLC     0  
    Venrock Healthcare Capital Partners EG, L.P.     0  
    VHCP Management II, LLC     0  
    VHCP Management III, LLC     0  
    VHCP Management EG, LLC     0  
    Nimish Shah     0  
    Bong Koh     0  

      

     
    CUSIP No. 45790W108Page 15 of 17

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9. Notice of Dissolution of a Group

     

    Not Applicable

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. 

     

     
    CUSIP No. 45790W108Page 16 of 17

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

    Venrock Healthcare Capital Partners II, L.P.   Venrock Healthcare Capital Partners III, L.P.
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: General Partner   Its: General Partner
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Co-Investment Holdings II, LLC   VHCP Co-Investment Holdings III, LLC
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: Manager   Its: Manager
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Management II, LLC   VHCP Management III, LLC
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Venrock Healthcare Capital Partners EG, L.P.   VHCP Management EG, LLC
         
    By: VHCP Management EG, LLC   /s/ Sherman G. Souther
    Its: General Partner   Name:   Sherman G. Souther
        Its:   Authorized Signatory
    /s/ Sherman G. Souther    
    Name:   Sherman G. Souther    
    Its:   Authorized Signatory    

     

    Bong Koh    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    
         
    Nimish Shah    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    

      

     
    CUSIP No. 45790W108Page 17 of 17

     

    EXHIBITS

     

    A:Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on April 29, 2022)

     

    B:Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed on April 29, 2022)

     

    C:Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on April 29, 2022)

      

     

     

     

    Get the next $INZY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INZY

    DatePrice TargetRatingAnalyst
    12/12/2024$26.00Outperform
    Raymond James
    9/12/2024$16.00Buy
    Stifel
    8/13/2024$16.00 → $17.00Buy
    Jefferies
    5/30/2024$14.00Overweight
    Wells Fargo
    3/23/2023$4.50 → $6.00Hold → Buy
    Jefferies
    5/26/2022$5.00Hold
    Jefferies
    2/7/2022$33.00Buy
    HC Wainwright & Co.
    11/29/2021$23.00Buy
    Needham
    More analyst ratings

    $INZY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James initiated coverage on Inozyme Pharma with a new price target

      Raymond James initiated coverage of Inozyme Pharma with a rating of Outperform and set a new price target of $26.00

      12/12/24 8:10:19 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Inozyme Pharma with a new price target

      Stifel initiated coverage of Inozyme Pharma with a rating of Buy and set a new price target of $16.00

      9/12/24 7:42:17 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Inozyme Pharma with a new price target

      Jefferies resumed coverage of Inozyme Pharma with a rating of Buy and set a new price target of $17.00 from $16.00 previously

      8/13/24 7:33:31 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INZY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioMarin Announces Completion of Acquisition of Inozyme

      SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (NASDAQ:INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. On May 16, 2025, BioMarin and Inozyme announced tha

      7/1/25 8:45:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

      BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the "Annual Meeting"), which was scheduled to be held on June 25, 2025, in light of the previously announced acquisition (the "Acquisition") by BioMarin Pharmaceutical Inc. ("BioMarin"). If the Acquisition is completed, there will be no Annual Meeting involving public stockholders. If the Acquisition is not completed, the Board of Directors will take such further action as it deems appropriate to call and convene the Annual Meeting at a later date, including the establishment of a new record date for determining the stockholders entitl

      6/20/25 5:00:00 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

      Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages  Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif. and BOSTON, May 16, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Inozyme Pharma, Inc. (NASDAQ:INZY) announced today that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transa

      5/16/25 7:30:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INZY
    SEC Filings

    See more
    • SEC Form EFFECT filed by Inozyme Pharma Inc.

      EFFECT - Inozyme Pharma, Inc. (0001693011) (Filer)

      7/2/25 12:15:26 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Inozyme Pharma Inc.

      EFFECT - Inozyme Pharma, Inc. (0001693011) (Filer)

      7/2/25 12:15:16 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Inozyme Pharma Inc.

      25-NSE - Inozyme Pharma, Inc. (0001693011) (Subject)

      7/1/25 9:54:57 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INZY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, CFO & Head of BD Subramanian Sanjay closing all direct ownership in the company (SEC Form 4)

      4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

      7/3/25 7:16:07 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COO Winton Matthew closing all direct ownership in the company (SEC Form 4)

      4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

      7/3/25 7:08:49 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bolte Axel closing all direct ownership in the company (SEC Form 4)

      4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

      7/3/25 7:07:07 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INZY
    Leadership Updates

    Live Leadership Updates

    See more
    • Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights

      - Interim data from ENERGY 3 trial highlight INZ-701's potential to modify disease course in ENPP1 Deficiency, with sustained phosphate increases and favorable safety and immunogenicity profile to date - - ENERGY 3 trial on track for topline data in first quarter of 2026; no patient dropouts, dose adjustments or discontinuations, and no new safety signals - - Petra Duda, M.D., Ph.D. appointed Chief Medical Officer - BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today reported financi

      5/14/25 7:30:00 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

      - Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected in early 2026 - - Company plans to initiate registrational trials in calciphylaxis and ABCC6 Deficiency in 2025 subject to regulatory alignment and sufficient funding - - Cash, cash equivalents, and short-term investments as of September 30, 2024, expected to fund operations into the fourth quarter of 2025 – BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical c

      11/5/24 8:30:00 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors

      BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced the appointment of Erik Harris to its Board of Directors, effective October 3, 2024. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings to Inozyme over 20 years of commercial expertise within the biopharma industry. "It is a privilege to welcome Erik to the Inozyme Board of Directors at this exciting juncture for Inozyme as we continue to lay the groundwork for ou

      10/7/24 8:30:17 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INZY
    Financials

    Live finance-specific insights

    See more
    • BioMarin Announces Completion of Acquisition of Inozyme

      SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (NASDAQ:INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. On May 16, 2025, BioMarin and Inozyme announced tha

      7/1/25 8:45:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

      Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages  Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif. and BOSTON, May 16, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Inozyme Pharma, Inc. (NASDAQ:INZY) announced today that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transa

      5/16/25 7:30:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

      - Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study highlights stroke as common feature among patients with early-onset ABCC6 Deficiency - - Favorable safety, immunogenicity and clinical outcome data were maintained through 48 weeks in Cohorts 1-3 in ENPP1 Deficiency; Data from Cohort 4 support once weekly dosing in ongoing and future clinical trials - - Company to host conference call and webcast today at 8:00 a.m. ET - BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage

      4/8/24 6:30:35 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INZY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Inozyme Pharma Inc.

      SC 13G - Inozyme Pharma, Inc. (0001693011) (Subject)

      12/9/24 4:14:49 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Inozyme Pharma Inc.

      SC 13G/A - Inozyme Pharma, Inc. (0001693011) (Subject)

      11/14/24 12:19:37 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Inozyme Pharma Inc.

      SC 13G - Inozyme Pharma, Inc. (0001693011) (Subject)

      10/24/24 2:02:10 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care